Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome

European Journal of Clinical Microbiology and Infectious Diseases

Volumn 33, Issue 8, 2014, Pages 1381-1390

  Flanagan, L ^a   Schmid, J ^a   Ebert, M ^b   Soucek, P ^c,d   Kunicka, T ^d   Liska, V ^d   Bruha, J ^d   Neary, P ^e   Dezeeuw, N ^e   Tommasino, M ^f   Jenab, M ^f   Prehn, J H M ^a   Hughes, D J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

^e ADELAIDE AND MEATH HOSPITAL   (Ireland)

^f INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; B RAF KINASE; BRAF PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; ONCOPROTEIN; PROTEIN P53; RAS PROTEIN; TP53 PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CARCINOGENESIS; COLORECTAL ADENOMA; COLORECTAL CANCER; CONTROLLED STUDY; DNA EXTRACTION; FEMALE; FUSOBACTERIUM INFECTION; FUSOBACTERIUM NUCLEATUM; FUSOBACTERIUM NUCLEATUM INFECTION; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR BIOPSY; ADENOMA; BACTERIAL LOAD; COHORT ANALYSIS; COLORECTAL TUMOR; DISEASE COURSE; FECES; GENETICS; ISOLATION AND PURIFICATION; KAPLAN MEIER METHOD; MICROBIOLOGY; MIDDLE AGED; MISSENSE MUTATION; MOLECULAR TYPING; MORTALITY; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOMA; AGED; AGED, 80 AND OVER; BACTERIAL LOAD; COHORT STUDIES; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; FECES; FEMALE; FUSOBACTERIUM NUCLEATUM; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; MOLECULAR TYPING; MUTATION, MISSENSE; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; RAS PROTEINS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84903817580     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/s10096-014-2081-3     Document Type: Article

References (40)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24(14):2137-2150. doi:10.1200/JCO. 2005.05.2308
2. Ferlay J, Shin HR, Bray F, Forman D,Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127(12):2893-2917. doi:10.1002/ijc.25516
3. Winawer SJ, Zauber AG (2002) The advanced adenoma as the primary target of screening. Gastrointest Endosc Clin N Am 12(1): 1-9, v (Pubitemid 34072776)
4. Kau AL, Ahern PP, Griffin NW, Goodman AL, Gordon JI (2011) Human nutrition, the gut microbiome and the immune system. Nature 474(7351):327-336. doi:10.1038/nature10213
5. Vipperla K, O'Keefe SJ (2012) The microbiota and its metabolites in colonic mucosal health and cancer risk. Nutr Clin Pract 27(5):624- 635. doi:10.1177/0884533612452012
6. Lepage P, Leclerc MC, Joossens M,Mondot S, Blottière HM, Raes J, Ehrlich D, Doré J (2013) A metagenomic insight into our gut's microbiome. Gut 62(1):146-158. doi:10.1136/gutjnl-2011-301805
7. Sokol H, Seksik P, Furet JP, Firmesse O, Nion-Larmurier I, Beaugerie L, Cosnes J, Corthier G, Marteau P, Doré J (2009) Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflamm Bowel Dis 15(8):1183-1189. doi:10.1002/ibd.20903
8. Kassinen A, Krogius-Kurikka L,Mäkivuokko H, Rinttilä T, Paulin L, Corander J, Malinen E, Apajalahti J, Palva A (2007) The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133(1):24-33. doi: 10.1053/j.gastro.2007.04.005 (Pubitemid 47031125)
9. Malinen E, Rinttilä T, Kajander K, Mättö J, Kassinen A, Krogius L, Saarela M, Korpela R, Palva A (2005) Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100(2):373-382. doi:10.1111/j. 1572-0241.2005.40312.x
10. Nyangale EP, Mottram DS,Gibson GR (2012) Gutmicrobial activity, implications for health and disease: the potential role of metabolite analysis. J Proteome Res 11(12):5573-5585. doi:10.1021/pr300637d
11. Marchesi JR, Dutilh BE, Hall N, Peters WH, Roelofs R, Boleij A, Tjalsma H (2011) Towards the human colorectal cancer microbiome. PLoS One 6(5):e20447. doi:10.1371/journal.pone.0020447
12. Arthur JC, Perez-Chanona E, Mühlbauer M, Tomkovich S, Uronis JM, Fan TJ, Campbell BJ, Abujamel T, Dogan B, Rogers AB, Rhodes JM, Stintzi A, Simpson KW, Hansen JJ, Keku TO, Fodor AA, Jobin C (2012) Intestinal inflammation targets cancer-inducing activity of the microbiota. Science 338(6103):120-123. doi:10.1126/ science.1224820
13. Wang T, Cai G, Qiu Y, Fei N, Zhang M, Pang X, Jia W, Cai S, Zhao L (2012) Structural segregation of gut microbiota between colorectal cancer patients and healthy volunteers. ISME J 6(2):320-329. doi:10. 1038/ismej.2011.109
14. Meucci G, Tatarella M, Vecchi M, Ranzi ML, Biguzzi E, Beccari G, Clerici E, de Franchis R (1997) High prevalence of Helicobacter pylori infection in patients with colonic adenomas and carcinomas. J Clin Gastroenterol 25(4):605-607 (Pubitemid 28051595)
15. Swidsinski A, Khilkin M, Kerjaschki D, Schreiber S, Ortner M, Weber J, Lochs H (1998) Association between intraepithelial Escherichia coli and colorectal cancer. Gastroenterology 115(2): 281-286 (Pubitemid 28363420)
16. Konstantinov SR, Kuipers EJ, Peppelenbosch MP (2013) Functional genomic analyses of the gut microbiota for CRC screening. Nat Rev Gastroenterol Hepatol 10(12):741-745. doi:10.1038/nrgastro.2013.178
17. Scanlan PD, Shanahan F, Clune Y, Collins JK, O'Sullivan GC, O'Riordan M, Holmes E, Wang Y, Marchesi JR (2008) Cultureindependent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol 10(3):789-798. doi:10.1111/j.1462- 2920.2007.01503.x
18. Jobin C (2013) Colorectal cancer: looking for answers in the microbiota. Cancer Discov 3(4):384-387. doi:10.1158/2159-8290.CD-13- 0042
19. Sobhani I, Amiot A, Le Baleur Y, Levy M, Auriault ML, Van Nhieu JT, Delchier JC (2013)Microbial dysbiosis and colon carcinogenesis: could colon cancer be considered a bacteria-related disease? Therap Adv Gastroenterol 6(3):215-229. doi:10.1177/1756283X12473674
20. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R,Watson P, Allen-Vercoe E, Moore RA, Holt RA (2012) Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 22(2):299-306. doi:10.1101/gr.126516.111
21. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M (2012) Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 22(2):292-298. doi:10.1101/gr.126573.111
22. Citron DM (2002) Update on the taxonomy and clinical aspects of the genus Fusobacterium. Clin Infect Dis 35(Suppl 1):S22-S27. doi:10.1086/341916
23. Moore WE, Moore LV (1994) The bacteria of periodontal diseases. Periodontol 2000 5:66-77
24. Swidsinski A, Dörffel Y, Loening-Baucke V, Tertychnyy A, Biche-Ool S, Stonogin S, Guo Y, Sun ND (2012) Mucosal invasion by fusobacteria is a common feature of acute appendicitis in Germany, Russia, and China. Saudi J Gastroenterol 18(1):55-58. doi:10.4103/ 1319-3767.91734
25. Roberts GL (2000) Fusobacterial infections: an underestimated threat. Br J Biomed Sci 57(2):156-162
26. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, DeVinney R, Lynch T, Allen-Vercoe E (2011) Invasive potential of gut mucosaderived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 17(9):1971-1978. doi:10.1002/ibd.21606
27. Han YW, Shi W, Huang GT, Kinder Haake S, Park NH, Kuramitsu H, Genco RJ (2000) Interactions between periodontal bacteria and human oral epithelial cells: Fusobacterium nucleatum adheres to and invades epithelial cells. Infect Immun 68(6):3140-3146 (Pubitemid 30340401)
28. Dharmani P, Strauss J, Ambrose C, Allen-Vercoe E, Chadee K (2011) Fusobacteriumnucleatum infection of colonic cells stimulates MUC2 mucin and tumor necrosis factor alpha. Infect Immun 79(7):2597-2607. doi:10.1128/IAI. 05118-11
29. McCoy AN, Araújo-Pérez F, Azcárate-Peril A, Yeh JJ, Sandler RS, Keku TO (2013) Fusobacterium is associated with colorectal adenomas. PLoS One 8(1):e53653. doi:10.1371/journal.pone.0053653
30. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS (2013) Fusobacteriumnucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 14(2):207-215
31. Rubinstein MR, Wang X, Liu W, Hao Y, Cai G, Han YW (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta- catenin signaling via its FadA adhesin. Cell Host Microbe 14(2):195-206. doi:10.1016/j.chom.2013.07.012
32. Huber S, Gagliani N, Zenewicz LA, Huber FJ, Bosurgi L, Hu B, Hedl M, Zhang W, O'Connor W Jr, Murphy AJ, Valenzuela DM, Yancopoulos GD, Booth CJ, Cho JH, Ouyang W, Abraham C, Flavell RA (2012) IL-22BP is regulated by the inflammasome and modulates tumorigenesis in the intestine.Nature 491(7423):259-263. doi:10.1038/nature11535
33. Sharara AI, Abou Hamdan T, Malli A, El-Halabi MM, Hashash JG, Ghaith OA, Kanj SS (2013) Association of Streptococcus bovis endocarditis and advanced colorectal neoplasia: a case-control study. J Dig Dis 14(7):382-387. doi:10.1111/1751-2980.12059
34. Gentili V, Gianesini S, Balboni PG, Menegatti E, Rotola A, Zuolo M, Caselli E, Zamboni P, Di Luca D (2012) Panbacterial real-time PCR to evaluate bacterial burden in chronic wounds treated with Cutimed™ Sorbact™. Eur J Clin Microbiol Infect Dis 31(7):1523- 1529. doi:10.1007/s10096-011-1473-x
35. Arumugam M, Raes J, Pelletier E, Le Paslier D, Yamada T, Mende DR, Fernandes GR, Tap J, Bruls T, Batto JM, Bertalan M, Borruel N, Casellas F, Fernandez L, Gautier L, Hansen T, Hattori M, Hayashi T, Kleerebezem M, Kurokawa K, Leclerc M, Levenez F,Manichanh C, Nielsen HB, Nielsen T, Pons N, Poulain J, Qin J, Sicheritz-Ponten T, Tims S, Torrents D, Ugarte E, Zoetendal EG, Wang J, Guarner F, Pedersen O, de Vos WM, Brunak S, Doré J; MetaHIT Consortium, Antolín M, Artiguenave F, Blottiere HM, Almeida M, Brechot C, Cara C, Chervaux C, Cultrone A, Delorme C, Denariaz G, Dervyn R, Foerstner KU, Friss C, van de Guchte M,Guedon E,Haimet F, Huber W, van Hylckama-Vlieg J, Jamet A, Juste C, Kaci G, Knol J, Lakhdari O, Layec S, Le Roux K, Maguin E, Mérieux A, Melo Minardi R, M'Rini C, Muller J, Oozeer R, Parkhill J, Renault P, Rescigno M, Sanchez N, Sunagawa S, Torrejon A, Turner K, Vandemeulebrouck G, Varela E, Winogradsky Y, Zeller G, Weissenbach J, Ehrlich SD, Bork P (2011) Enterotypes of the human gut microbiome. Nature 473(7346):174 - 180. doi:10.1038/nature09944
36. Terry MB, Neugut AI, Bostick RM, Sandler RS, Haile RW, Jacobson JS, Fenoglio-Preiser CM, Potter JD (2002) Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 11(7):622-629 (Pubitemid 34760820)
37. Hill MJ, Morson BC, Bussey HJ (1978) Aetiology of adenoma - carcinoma sequence in large bowel. Lancet 1(8058):245-247 (Pubitemid 8268162)
38. Wu N, Yang X, Zhang R, Li J, Xiao X, Hu Y, Chen Y, Yang F, Lu N, Wang Z, Luan C, Liu Y,Wang B, Xiang C,Wang Y, Zhao F, Gao GF, Wang S, Li L, Zhang H, Zhu B (2013) Dysbiosis signature of fecal microbiota in colorectal cancer patients.Microb Ecol 66(2):462-470. doi:10.1007/s00248-013-0245-9
39. Zoetendal EG, von Wright A, Vilpponen-Salmela T, Ben-Amor K, Akkermans AD, de Vos WM (2002) Mucosa-associated bacteria in the human gastrointestinal tract are uniformly distributed along the colon and differ from the community recovered from feces. Appl Environ Microbiol 68(7):3401-3407 (Pubitemid 34734038)
40. Peyret-Lacombe A, Brunel G, Watts M, Charveron M, Duplan H (2009) TLR2 sensing of F. nucleatum and S. sanguinis distinctly triggered gingival innate response. Cytokine 46(2):201-210. doi:10. 1016/j.cyto.2009.01.006